Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation

Content Provider	Semantic Scholar
Author	Masago, K. Togashi, Yosuke Fukudo, Masahide Terada, Tomohiro Irisa, Kaoru Sakamori, Yuichi Fujita, Shiro Kim, Young Hak Mio, Tadashi Inui, Ken-Ichi Mishima, Michiaki
Copyright Year	2010
Abstract	Recently, 2 small molecule kinase inhibitors (TKIs), targeting epidermal growth factor receptor (EGFR), have proven effective in the treatment of non-small cell lung cancer. However, it is unknown whether the EGFR double activating mutation of L858R in exon 21 and the in-frame deletion in exon 19 is a predictor of the effectiveness of EGFR-TKIs. We report for the first time a case of non-small cell lung cancer with central nervous system metastases harboring a rare EGFR double activating mutation who showed a good clinical response to erlotinib, regardless of his poor performance status, as swallowing is not possible. Therefore, we suggest that erlotinib may become a therapeutic choice in cases of central nervous system metastases even with poor performance status.
Starting Page	98
Ending Page	105
Page Count	8
File Format	PDF HTM / HTML
Alternate Webpage(s)	https://www.karger.com/Article/Pdf/310830
PubMed reference number	20740181v1
Volume Number	3
Journal	Case reports in oncology
Language	English
Access Restriction	Open
Subject Keyword	CNS disorder CNS metastases Deletion Mutation Diploid Cell EGFR protein, human Exons Growth Factor Receptors Metastatic malignant neoplasm to brain Nervous system structure Non-Small Cell Lung Carcinoma Small Molecule Small cell carcinoma of lung Status Epilepticus cellular targeting erlotinib pediatric intracranial germ cell brain tumor
Content Type	Text
Resource Type	Article